Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Methods A systematic search was conducted using the Medline® and Embase® databases
up to 30 June 2017 employing specific medical subject heading terms. Additionally, the …

Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …

Objectives To assess the efficacy and safety of switching from the infliximab reference
product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 …

Biosimilars of infliximab were first approved by the European Medicine Agency in 2013, 1, 2
based on pre-clinical studies on biosimilarity and on clinical data coming from two …

Objectives According to guidelines, a nationwide non-medical switch from originator (INX,
Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients …

To date, no consensus exists among stakeholders about switching patients between
reference biological products (RPs) and biosimilars, which may have been curbing the …

The study aimed to develop evidence-based recommendations regarding the evaluation
and use of biosimilars to treat rheumatological diseases. The task force comprised an expert …

Objective To update the evidence on efficacy and safety of biological disease-modifying
antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the …

Background Biosimilars have been used for 15 years in the European Union (EU), and have
been shown to reduce costs and increase access to important biological medicines. In spite …